Immunomodulatory Treatment Approaches for Myelodysplastic Syndromes
A variety of immune pathways mediate the pathogenesis of myelodysplastic syndromes, suggesting that the immune system may be a feasible therapeutic target.
Myelodysplastic Syndromes
MYELODYSPLASTIC SYNDROMES
FEATURE
LATEST NEWS
Intensive Chemotherapy May Be Beneficial for Younger Patients With Myelodysplastic Syndrome
Compared with hypomethylating agents, intensive chemotherapy was associated with higher overall response and complete remission rates.
EBV Reactivation After Transplant Associated With Worse Clinical Outcomes in Myelodysplastic Syndrome
Patients who experienced reactivation of Epstein-Barr virus also experienced inferior relapse-free survival and increased incidence of relapse.
No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
Results from a systematic review and meta-analysis published in Critical Reviews in Oncology/Hematology indicated there was no association between mutations in SF3B1 and overall survival (OS) in patients with myelodysplastic syndrome (MDS). Mutations in the SF3B1 gene are the most common mutations in MDS, though the prognostic implications of these mutations are unclear. In this…
Prolonged-Release Anagrelide May Be Safe and Efficacious Against Thrombocythemia
Prolonged-release administration of anagrelide resulted in a noninferior decrease in mean platelet levels compared with immediate-release administration.
Treating Myelodysplastic Syndrome After Failure of Hypomethylating Agents: Options Remain Limited
There is a pressing need to develop novel therapeutic strategies for patients with myelodysplastic syndrome who are ineligible for transplantation.
Proposed Updates to Treatment Response Criteria for Patients With Myelodysplastic Syndromes
The current set of standardized treatment response criteria was most recently revised in 2006 and had many shortcomings when applied to clinical trials.
Eltrombopag Plus Azacitidine May Lead to Worse Survival in Patients With Myelodysplastic Syndrome
Up to 65% of patients with myelodysplastic syndrome experience comorbid thrombocytopenia.
Immunosuppressive Therapy May Predict Improved Survival in Myelodysplastic Syndromes
Immunosuppressive therapy is used sparingly due to the operational challenges in administration and prediction of patient benefit.
Mutations After Transplant in Myelodysplastic Syndrome May Correlate With Progressed Disease
The presence of persistent disease-related mutations 30 days after ASCT for myelodysplastic syndrome was associated with higher risk of disease progression.
Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
MDS, AML a Risk With PARP Inhibitors in BRCA Mutation Carriers
What is the concern behind PARP inhibitors and leukemia?
Alcohol May Reduce Risk of Myelodysplastic Syndrome
Smoking may slightly increase the risk for myelodysplastic syndromes, but alcohol consumption may be significantly protective against MDS.
DSP-7888 Granted Orphan Drug Status for Myelodysplastic Syndrome
The US Food and Drug Administration granted orphan drug designation to DSP-7888 for myelodysplastic syndrome.
Reduced-intensity Conditioning for Stem Cell Transplantation Effective in MDS
The results of this study suggest that RIC may be an alternative to MAC, particularly for patients of low cytogenetic risk.
Complex Karyotype, TP53 Mutations Associated With HCT Outcomes in Myelodysplasia
Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.
Eltrombopag for Lower-risk MDS With Severe Thrombocytopenia
Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.
Want to read more?
Please login or register first to view this content.
Next post in Myelodysplastic Syndromes
